Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …

For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained
the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Dual antiplatelet therapy—the combination of aspirin and a P2Y 12-receptor inhibitor—is the
cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those …

Precision medicine is a medical model that proposes the customization of medical
treatments to the individual patient, as opposed to a one-drug-fits-all model. Such a …

Dual antiplatelet therapy (DAPT) represents the standard of care for patients undergoing
percutaneous coronary intervention (PCI). Increasing evidence indicates that a “one-size-fits …

Antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of
pharmacological treatment to optimize clinical outcomes in patients with ST-segment …

The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1
blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor …

The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing
percutaneous coronary intervention with stent implantation is an emerging clinical problem …

Introduction Clopidogrel is the most frequently utilized P2Y12 inhibitor and is characterized
by broad interindividual response variability resulting in impaired platelet inhibition and …